Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs by Brommesson, Sara et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Clinical Pathology
Open Access Research article
Tiling array-CGH for the assessment of genomic similarities among 
synchronous unilateral and bilateral invasive breast cancer tumor 
pairs
Sara Brommesson1, Göran Jönsson1,2, Carina Strand1, Dorthe Grabau3, 
Per Malmström1, Markus Ringnér1,2, Mårten Fernö1 and Ingrid Hedenfalk*1
Address: 1Division of Oncology, Department of Clinical Sciences, Lund University, SE-221 85 Lund, Sweden, 2CREATE Health Strategic Centre for 
Clinical Cancer Research, Lund University, SE-221 85 Lund, Sweden and 3Division of Pathology, Department of Clinical Sciences, Lund University, 
SE-221 85 Lund, Sweden
Email: Sara Brommesson - Sara.Brommesson@med.lu.se; Göran Jönsson - Goran_B.Jonsson@med.lu.se; 
Carina Strand - Carina.Strand@med.lu.se; Dorthe Grabau - Dorthe.Grabau@skane.se; Per Malmström - Per.Malmstrom@med.lu.se; 
Markus Ringnér - Markus.Ringner@med.lu.se; Mårten Fernö - Marten.Ferno@med.lu.se; Ingrid Hedenfalk* - Ingrid.Hedenfalk@med.lu.se
* Corresponding author    
Abstract
Background: Today, no objective criteria exist to differentiate between individual primary tumors and
intra- or intermammary dissemination respectively, in patients diagnosed with two or more synchronous
breast cancers. To elucidate whether these tumors most likely arise through clonal expansion, or whether
they represent individual primary tumors is of tumor biological interest and may have clinical implications.
In this respect, high resolution genomic profiling may provide a more reliable approach than conventional
histopathological and tumor biological factors.
Methods: 32 K tiling microarray-based comparative genomic hybridization (aCGH) was used to explore
the genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs, and
was compared with histopathological and tumor biological parameters.
Results: Based on global copy number profiles and unsupervised hierarchical clustering, five of ten (p =
1.9 × 10-5) unilateral tumor pairs displayed similar genomic profiles within the pair, while only one of eight
bilateral tumor pairs (p = 0.29) displayed pair-wise genomic similarities. DNA index, histological type and
presence of vessel invasion correlated with the genomic analyses.
Conclusion:  Synchronous unilateral tumor pairs are often genomically similar, while synchronous
bilateral tumors most often represent individual primary tumors. However, two independent unilateral
primary tumors can develop synchronously and contralateral tumor spread can occur. The presence of an
intraductal component is not informative when establishing the independence of two tumors, while vessel
invasion, the presence of which was found in clustering tumor pairs but not in tumor pairs that did not
cluster together, supports the clustering outcome. Our data suggest that genomically similar unilateral
tumor pairs may represent a more aggressive disease that requires the addition of more severe treatment
modalities, and underscores the importance of evaluating the clonality of multiple tumors for optimal
patient management. In summary, our findings demonstrate the importance of evaluating the properties
of both tumors in order to determine the most optimal patient management.
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Background
The incidence of synchronous bilateral breast cancer is
low, corresponding to less than 2% of all breast cancer
diagnoses [1-3]. The definition of synchronism in this
context is, however, ambiguous in the literature, and the
time spans used to define breast cancers as synchronous
range from one month to two years, making the interpre-
tation of incidence difficult [4-6]. In this study we define
synchronously diagnosed breast cancer as the occurrence
of two (or more) tumors at primary surgery without a
prior history of breast cancer. Synchronous multiple
tumors in the same breast are often described as multi-
focal or multi-centric (multiple tumors in the same quad-
rant or in different quadrants of the breast, respectively)
and are thought to develop much more often than syn-
chronous bilateral breast tumors. Between one-fourth and
half of all patients with breast cancer have been reported
to have another carcinoma focus in the same breast in
addition to the index tumor [7,8].
When multiple breast tumors are detected synchronously
the question arises whether these tumors represent inde-
pendent primary lesions or whether they are genetically
similar. Chaudary et al. have set up criteria used to dis-
criminate between independent primary lesions and
metastases in synchronous bilateral breast cancer [1].
Bilateral carcinomas are considered independent: 1) if
both tumors have in situ components, or 2) if the lesions
are of different histological types, or 3) if the lesions have
different degrees of histological differentiation, and 4)
there is no evidence of regional or distant metastases.
However, from a clinical perspective, bilateral tumors are
most often considered separate tumours due to the lim-
ited information obtained from the criteria above. In clin-
ical routine, adjuvant medical therapy is recommended
on the basis of tumor biological characteristics of both
tumors and adjuvant radiotherapy on type of surgery and
number of lymph nodes with metastases. Contralateral
metastasis as a first event is very rare, but cannot be com-
pletely excluded if the two tumors appear histologically
very similar.
To discriminate primary lesions from metastatic spread
with multiple carcinomas in the same breast is however
more difficult as tumor histology is in most cases incon-
clusive, although the presence of an intraductal compo-
nent in each of the lesions suggests independent origins
[7]. Other parameters, such as the separation of the
lesions by uninvolved breast tissue and the location of the
foci in different quadrants of the breast have also been
considered indicators of independent primary lesions
[7,8]. Adjuvant therapy for multiple unilateral tumors is
tailored to the tumor with the worst prognosis, most often
the largest tumor, and the presence of lymph node metas-
tases. It was recently shown that unilateral multicentricity
was a risk factor for local recurrence in young patients
treated with breast conserving surgery [9], emphasizing
the clinical significance of this diagnosis.
Studying genetic alterations may provide a more objective
assessment when discerning clonal relationships between
multiple tumors, or may serve as a complement to existing
histopathological evaluations. Methods including X chro-
mosome inactivation analysis, comparisons of allelic
imbalance patterns [10-13], or the distribution of p53
mutations [14,15] have all been used to address this issue.
These studies illustrate that more tumors can be classified
as either primary lesions or metastatic spread with the
additional analysis of genetic markers, but the concord-
ance with conventional histopathological analysis is low
and neither of these methods has given an overall objec-
tive assessment of tumor clonality. More recently, karyo-
typing [8] and metaphase comparative genomic
hybridization (CGH) [16,17] have been applied to
address the extent of genetic relationship between multi-
ple breast tumors on a genome-wide scale. Using CGH, it
was shown that unilateral (multi-focal) tumors usually
were more genetically similar to each other than bilateral
tumors, indicating that unilateral tumors more often rep-
resent intramammary dissemination of a single breast
cancer [16]. Metaphase CGH however, only shows copy
number gains and losses and not individual gene amplifi-
cations or deletions, and the technique is hampered by
limited resolution (10–20 Mb). Improvements in resolu-
tion and sensitivity of copy number aberrations have
recently been made possible through microarray-based
CGH (aCGH) [18], which could potentially serve as an
important complement to histopathological diagnoses of
multiple synchronous breast tumors as recently illustrated
by Ghazani and colleagues [19]. To this end, Wa et al. used
aCGH to study the relationship between two synchronous
unilateral breast tumors in a single patient and found the
genetic analysis to clearly demonstrate the occurrence of
two independent lesions [20].
To our knowledge very little has been published regarding
biological characteristics of synchronously diagnosed
multiple unilateral and bilateral breast cancer, with the
definition of synchronous being no time elapsed between
surgical excision of the tumors, i.e. without potential
interference of adjuvant medical treatment. The present
study is the first using high resolution genomic profiling
to investigate genomic similarities between tumor pairs
from the same patient in a cohort of synchronous unilat-
eral as well as bilateral breast cancers, in combination
with histopathological evaluation. The aim of this study
was to address the issue of genetic similarity in synchro-
nously diagnosed unilateral (multi-focal or multi-centric)
and bilateral breast cancer using tiling resolution aCGH,
with the ultimate goal of determining tumor clonality andBMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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whether this information can be of clinical significance
when making treatment decisions. In addition, the assess-
ment of genomic similarities/dissimilarities was evaluated
in relation to conventional histopathological and tumor
biological parameters to determine the level of concord-
ance between the genetic evaluation and commonly used
histopathological criteria. Our findings demonstrate the
importance of evaluating the properties of both tumors in
order to determine the most optimal management of the
patient.
Methods
Patients and tumors
Patients diagnosed with synchronous unilateral or bilat-
eral breast tumors between 1987 and 2006 at Lund Uni-
versity Hospital from whom sufficient material from both
tumors was available in the Southern Sweden Breast Can-
cer Group's tissue bank at the Departments of Oncology
and Pathology, Lund University Hospital, were included
in the study. In addition, formalin-fixed, paraffin-embed-
ded (FFPE) tumor pairs from a small number of patients
from the same institution were included to increase sam-
ple numbers. Within all pairs, both tumors were either
fresh frozen (n = 15 pairs) or FFPE (n = 3 pairs). We
defined synchronously diagnosed breast cancer tumors as
having the same date of surgical excision. A total of 33
tumors, representing tumor pairs from 16 patients, were
analyzed. One of the 16 patients had three synchronous
tumors (two in the left breast and one in the right), which
for the subsequent analyses resulted in one unilateral
tumor pair and two bilateral tumor pairs from this
patient. Unilateral breast cancer was defined as two dis-
crete tumors in the same breast separated by at least 1 cm
of normal tissue. Altogether, ten unilateral tumor pairs
and eight bilateral tumor pairs were included in the anal-
yses. Two lymph nodes from patients in the cohort were
included to obtain a measurement of genomic similarity
(FFPE material). Only one patient (patient 15) received
pre-operative treatment; radiotherapy and neo-adjuvant
chemotherapy (ACFUMx6; adriamycin, cyclophospha-
mide, 5-fluorouracil, metothrexate). A family history of
breast cancer was only known for one patient (patient 2).
The study was approved by the Lund University ethics
committee.
Histopathology and immunohistochemistry
All samples were re-evaluated by a pathologist (DG) to
confirm histological type and grade (Nottingham histo-
logical grade, NHG) [21] presence or absence of an intra-
ductal component, vessel invasion (based on H&E stained
sections), tumor size and nodal status, according to rou-
tine practice. Estrogen receptor (ER) and progesterone
receptor (PgR) status were determined by enzyme immu-
noassay (fresh frozen tissue, according to Abbott Labora-
tories (Chicago, IL)), or by immunohistochemical assay
(FFPE tissue), and routine DNA index (flow cytometric
DNA analysis) was assessed prospectively according to
standard procedures as previously described [22-24].
DNA isolation
Genomic DNA was isolated from frozen and FFPE tissue
using proteinase K followed by the Wizard Genomic DNA
extraction kit and phenol chloroform purification accord-
ing to the manufacturer's protocols (Promega Corpora-
tion, Madison, WI), and DNA concentrations were
measured using the NanoDrop Spectrophotometer (Nan-
oDrop Technologies, Wilmington, DE). To test the DNA
integrity from FFPE tissue, an amplification according to a
random amplified polymorphic protocol (Amersham
Bioscience, Piscataway, NJ) was performed; DNA quality
was then tested using the Agilent DNA 1000 Kit with the
Agilent BioAnalyzer 2100 system (Agilent Technologies,
Santa Clara, CA). Visual inspection of the electrophero-
grams was performed, and samples with unsatisfactory
DNA quality were excluded.
Array comparative genomic hybridization
Microarrays with complete tiling genomic coverage were
produced from the 32 K BAC clone library (CHORI
BACPAC Resources [25]) at the Swegene DNA Microarray
Resource Centre, Department of Oncology, Lund Univer-
sity, Sweden. Mapping data for each clone was based on
the UCSC May 2004 assembly (hg17). Arrays were con-
structed as described elsewhere [26]. Three μg of genomic
DNA from samples and two μg of male commercial refer-
ence DNA (Promega Corporation, Madison, WI) was
labeled and hybridized, and arrays were scanned accord-
ing to previously published protocols [27,28]. To account
for differences in dye incorporation with DNA from FFPE
tissue, dye swap experiments were performed for these
samples.
Data and image analysis
Gene Pix Pro 4.0 (Axon Instruments Inc., Union City, CA)
was used to identify individual spots on scanned arrays
and the data was processed and analyzed using BioArray
Software Environment BASE [29]. The Cy3 and Cy5 inten-
sities were background-corrected by calculating the
median-feature and median-local background intensities
provided in the quantified data matrix. Within each of the
arrays, ratios of intensity for individual probes were calcu-
lated as background corrected intensity of the sample,
divided by background corrected intensity of the reference
sample. Log(2)ratios were normalized and corrected for
intensity-based location adjustment [30]. The X and Y
chromosome BAC clones were excluded during the nor-
malization. To reduce experimental noise over the chro-
mosomal profile a moving average of 400,000 base pairs
was applied. A BASE implementation of CGH Plotter was
used to determine deletion/amplicon boundaries [31].BMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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Further evaluation of the genetic similarity/dissimilarity
between tumors from the same patient was performed by
unsupervised hierarchical clustering of segmented CGH
data. Clustering based on global genomic profiles was
performed with average linkage and Pearson correlation.
Statistical analysis
A random permutation test was performed to validate the
significance of the number of unilateral or bilateral tumor
pairs that exhibited a high degree of genomic similarity.
The sample labels of the arrays were randomly permuted,
whereupon the number of unilateral and bilateral tumor
pairs, respectively, that clustered together was calculated.
This procedure was performed 106 times. Using these per-
mutations, the actual numbers of unilateral and bilateral
tumor pairs that clustered together were assigned p-values
corresponding to the probability to obtain as many clus-
tered pairs or better under this null hypothesis of genomic
profiles randomly associated with sample labels.
Results
Array comparative genomic hybridization
Several non-random chromosomal aberrations were
found in the tumor cohort. The most commonly observed
gains were located on chromosomes 16p (50%), 8q
(45%), 1q (40%) and 10p (25%), whereas the most com-
mon losses were found on chromosomes 16q (45%), 21
(30%), 8p (30%) and 13 (25%). A summary of the
genomic aberrations of each individual tumor is provided
in Additional File 1 (Summary of genomic aberrations in
uni- and bilateral breast cancer tumor pairs). Due to the
preponderance of tumors with a high histological grade,
the prevalence of chromosomal aberrations was complex
in many samples.
Unsupervised hierarchical clustering analysis was used to
identify tumor pairs showing similar genome-wide DNA
copy number profiles (Figure 1A). The connection of two
tumor samples from the same patient on short branches
in the dendrogram indicates that these genetic profiles are
more similar to each other on a genome-wide basis than
to any other tumor sample in the cohort. To validate this
approach we included two matched lymph nodes to the
analysis. This resulted in a close clustering of the lymph
nodes with the tumors from the respective patients (Fig-
ure 1B), confirming their respective mutual genomic ori-
gins. The source of the DNA (i.e. from fresh frozen or FFPE
tissue; see Table 1) did not seem to affect the clustering
outcome, as tumor pairs from either source were found
among those that clustered as well as among the non-clus-
tering pairs. Such similarity measures have been found to
be useful for aCGH profiles [32,33], in particular for
tumor specimens as they often contain a varying degree of
stromal contamination. We were in the present investiga-
tion only interested in identifying tumor pairs that
appeared as pairs in the hierarchical clustering analysis.
Importantly, this approach is independent of the choice
of linkage method used.
Of the ten patients with two unilateral breast tumors (n =
7 frozen, n = 3 FFPE) a high degree of genomic similarity
was suggested within the tumor pairs of five patients (n =
2 frozen, n = 3 FFPE; Figure 1A; dark blue boxes). This is
significantly more than expected by random permutation
of the sample labels (p = 1.9 × 10-5). Notably, despite
numerous and complex chromosomal aberrations in
both tumors within these pairs, they clustered together.
Discrepancies in aberration amplitudes between the
tumors in the clustering pairs was, however, seen in some
cases, e.g. chromosomes 11q and 17 in tumor pair 6, and
chromosomes 5 and 8q in tumor pair 8 (Figure 2); but
since the assessment of genomic similarity is based on
patterns of aberrations, the amplitude does not affect the
outcome of the clustering analysis.
Among the bilateral tumor pairs, similarities in the
genome wide copy number profiles were only apparent in
one of eight tumor pairs (Figure 1A; orange box), which is
not significant compared to random expectations (p =
0.29). This tumor pair displayed a multitude of complex
chromosomal aberrations as well as variations in ampli-
tude (Figure 3; tumor pair 15).
Unilateral tumor pairs
Two of the five unilateral tumor pairs that did not cluster
together (of the ten unilateral pairs) demonstrated a high
degree of difference in chromosomal imbalances, suggest-
ing genetic heterogeneity, and hence that two synchro-
nously diagnosed unilateral breast tumors can have
different origins. An example of a tumor pair of possibly
different origins is tumor pair 2 where one tumor (2b)
harbored an ERBB2 amplification, whereas the other (2a)
did not. Also tumor pair 4 displayed a number of major
differences in copy number profiles (gain of chromosome
1 in tumor 4a, and chromosome 8 in tumor 4b, loss of
chromosome 9p in tumor 4a and chromosome 22 in
tumor 4b; see Figure 2), indicating unilateral tumor heter-
ogeneity.
For the remaining three pairs in the group that did not
cluster together, the tumors exhibited few chromosomal
aberrations; moreover these imbalances are commonly
found in breast tumors (e.g. gain of chromosome 1q, loss
of chromosomes 8 and 16q). Even small differences may
nonetheless have a profound effect on the clustering out-
come; e.g. despite only differing on chromosomes 5 and
8, the tumors within tumor pair 1 did not cluster together
(Figure 2). In addition, the slight differences between the
tumors on chromosomes 6, 8 and 22 in tumor pair 3
resulted in these tumors not clustering as a pair (Figure 2).BMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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The tumors from these two patients were all histological
grade 1, except tumor 1a which was histological grade 2.
Patient number 10 was diagnosed with three synchronous
breast tumors, two in the left breast and one in the right
breast, thereby giving rise to one unilateral tumor pair
(10a and b; Figure 2) and two bilateral tumor pairs (10a
and c, and 10b and c; Figure 3) for comparison. Neither of
these tumors clustered together, suggesting that the three
tumors all developed from different origins.
Of the five unilateral tumor pairs that exhibited similar
genomic profiles within the pair (of the ten unilateral
pairs), both tumors in all of the pairs were of the same his-
tological grade (grade 3; see Table 1). In addition, the
range in DNA indices showed only minor variations for
tumors that clustered together, while tumors that did not
cluster together showed a DNA index range with greater
degrees of variation (range: 2–10% vs. 0–61%). For two of
the pairs that did not cluster together, the evaluation of
Table 1: Patient and tumor characteristics.
Tumor Distance between 
tumors (cm)
Grade ER status PgR status DNA index Intraductal 
component
Node status Vessel invasion
Unilateral tumor pairs that do not cluster
1a 6 1 pos pos 1.61 yes neg no
1b§ 2 pos pos 1.00 no
2a 5 3 neg neg 1.80 yes neg no
2b 2 pos neg 1.58 yes
3a 4 1 pos pos 1.08 yes pos no
3b 1 pos pos 1.00 yes
4a§ n/a 2 pos pos 1.10 yes pos no
4b 2 pos pos 1.16 no
10a n/a 2 pos pos 1.00 yes pos no
10b 2 pos pos 1.00 yes
Unilateral tumor pairs that cluster
5a 2 3 neg neg 1.45 yes pos yes
5b 3 neg neg 1.56 yes
6a 1 3 pos pos 1.70 yes pos no
6b 3 pos pos 1.73 yes
7aγ 3 3 neg pos 1.98 yes neg yes
7bγ 3p o s p o s 1 . 8 1 y e s
8aγ 1 3 neg neg 2.50 yes pos yes
8bγ 3 neg neg 2.28 no
9aγ 8 3 pos pos 1.63 yes pos yes
9bγ 3p o s p o s 1 . 7 3 y e s
Bilateral tumor pairs that do not cluster
10a - 2 pos pos 1.00 yes pos no
10c 2 pos pos 1.00 yes neg no
10b 2 pos pos 1.00 yes pos no
10c 2 pos pos 1.00 yes neg no
11a - 1 pos neg 2.83 yes neg no
11b 3 pos neg 1.00 no pos no
12a - 3 pos pos 2.73 no neg no
12b 1 pos pos 1.89 no neg no
13a - 2 pos pos 1.09 yes pos no
13b 2 pos pos 1.00 yes pos no
14a - 2 pos pos 1.75 yes pos no
14b 2 pos pos 1.76 yes pos yes
16a - 1 pos pos 2.19 yes pos no
16b 2 neg neg 1.00 yes n/a no
Bilateral tumor pairs that cluster
15a - 3 neg neg 1.94 yes pos no
15b 3 pos pos 2.01 yes pos no
Patients are numbered consecutively and tumor pairs are denoted a and b, respectively. All tumors, except where otherwise indicated, were of 
ductal type. Unless otherwise indicated, all samples were from fresh frozen tissue.
§ lobular type
γ FFPEBMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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histological type differed between the tumors, one tumor
being ductal type and the other lobular type in these pairs.
All other tumors in the cohort were of ductal type.
Vessel invasion was observed in four of the ten unilateral
tumor pairs, all of which clustered together as pairs in the
genomic analysis (Table 1). Four of the five tumor pairs in
the group that exhibited genomic similarities had an
intraductal component in both tumors, while three of five
tumor pairs in the group that did not cluster together had
an intraductal component in both tumors (Table 1), sug-
gesting that the presence of an intraductal component in
the unilateral tumor pairs that cluster together represents
an intraductal growth phase rather than pre-invasive in
Unsupervised hierarchical clustering analysis of genomic similarities between synchronously diagnosed unilateral and bilateral  tumor pairs from 16 breast cancer patients Figure 1
Unsupervised hierarchical clustering analysis of genomic similarities between synchronously diagnosed unilat-
eral and bilateral tumor pairs from 16 breast cancer patients. A. Dark blue boxes represent unilateral tumor pairs 
from the same patient displaying genomic similarities. Light blue boxes represent genomically dissimilar unilateral tumor pairs. 
The orange box represents a bilateral tumor pair displaying genomic similarities, and yellow boxes represent genomically dis-
similar bilateral tumor pairs. Patient number 10 was diagnosed with three synchronous tumors, resulting in one unilateral 
tumor pair and two bilateral pairs (light blue and yellow boxes). B. The addition of two matched lymph nodes (white boxes 
marked by a red star) to the unsupervised hierarchical clustering analysis resulted in the two lymph nodes clustering with the 
tumor pair from the corresponding patient.
A.
B.BMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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Heatmaps of chromosomal aberrations in ten synchronously diagnosed unilateral breast tumor pairs Figure 2
Heatmaps of chromosomal aberrations in ten synchronously diagnosed unilateral breast tumor pairs. Gains/
amplifications are shown in red and losses/deletions in green. Dark blue boxes indicate genomically similar tumor pairs and 
light blue boxes indicate genomically dissimilar tumor pairs.
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Heatmaps of chromosomal aberrations in eight synchronously diagnosed bilateral breast tumor pairs Figure 3
Heatmaps of chromosomal aberrations in eight synchronously diagnosed bilateral breast tumor pairs. Gains/
amplifications are shown in red and losses/deletions in green. The orange box indicates the genomically similar tumor pair, and 
the yellow boxes indicate genomically dissimilar tumor pairs.
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situ cancer. Tumor size, hormone receptor status, distance
between tumors and lymph node status were inconclusive
or did not correlate with the results of the genomic simi-
larity analysis.
Bilateral tumor pairs
Only one of the eight bilateral pairs exhibited genomic
similarities in the clustering analysis; both tumors in this
pair contained an intraductal component and both were
histological grade 3. The DNA indices for these two
tumors were similar (1.94 and 2.01), and this patient had
positive lymph nodes on both right and left sides. For the
seven bilateral pairs that did not cluster together, four
were concordant with respect to histological grade within
the pair while three were not (Table 1). Three of the seven
pairs had a greater variation in DNA index between the
tumors than the clustering pairs (range 18–183%),
whereas the remaining four pairs only had a minor or no
variation in DNA index (range 0–9%). Five of the seven
tumor pairs that did not cluster had an intraductal com-
ponent in both tumors. The sixth patient had one tumor
that contained an intraductal component while the other
tumor did not, and in the seventh patient neither tumor
had an intraductal component; nevertheless this tumor
pair did not cluster together. As was the case for unilateral
tumors, bilateral tumor pairs that did not cluster together
(with the exception of tumor pair 14) had no vessel inva-
sion. Tumor size, hormone receptor status and lymph
node status were inconclusive or did not correlate with the
results of the genomic similarity analysis.
Discussion
CGH has greatly facilitated the detection of gains and
losses in DNA copy number, and is especially useful when
elucidating patterns of genomic alterations in tumors.
Since the extent of genomic imbalances can be deter-
mined with greater mapping precision due to the high res-
olution and large number of data points [19], aCGH in
particular may be of clinical value in differentiating new
primary tumors from recurrent lesions and genomic anal-
ysis can help reveal the relationship between multiple
tumors. Moreover, this may have significant implications
for selection of optimal adjuvant treatment. Today, differ-
ences in tumor histopathology are used to distinguish
between disseminated disease and the occurrence of mul-
tiple synchronous primary tumors. Recent reports, how-
ever, demonstrate that histopathological evaluation fails
to provide unambiguous evidence for tumor origin; hence
it has been proposed that genetic analyses are more relia-
ble in this context [9,14,16]. In the present study we elu-
cidated genomic alterations in synchronously diagnosed
unilateral and bilateral breast tumor pairs using 32 K til-
ing BAC aCGH. The analysis of tumor pairs from 10
patients diagnosed with synchronous unilateral breast
cancer by unsupervised hierarchical clustering resulted in
tumors from five patients clustering together as pairs, sug-
gesting a genomic similarity and a possible common ori-
gin of the two tumors in these patients. These tumor pairs
clustered together despite complex chromosomal copy
number aberrations. In line with our findings, previous
studies based on genetic as well as histopathological eval-
uations have concluded that a large fraction of unilateral
breast tumors arise through intramammary dissemination
of a single breast cancer, i.e. suggesting that most unilat-
eral tumors develop from the same clonal origin
[11,16,34-36]. More recently, similar results have been
obtained by analyzing unilateral breast tumors using met-
aphase CGH and unsupervised hierarchical clustering;
one such study revealed that paired tumors from three of
four unilateral breast cancer patients demonstrated a
clonal relatedness based on copy number profiles [16].
Alternatively, it is possible that the genomic similarities
observed in our study could be caused by a 'field effect'
whereby e.g. a common environmental exposure could
cause the development of genomically similar, but inde-
pendent, tumors. However, this appears less likely, as
such an environmental effect would be expected to affect
the similarity also among bilateral cases, which was not
the case. In our study, an absence of genomic similarities
was found in five of ten synchronous unilateral tumor
pairs, i.e. the two tumors from the same patient did not
cluster together. Two of these tumor pairs displayed
highly discordant chromosomal imbalances, emphasiz-
ing the possibility that the tumors have developed inde-
pendently. Alternatively, intra-tumor heterogeneity may
explain these differences, as recently suggested [17]. Based
on these findings we conclude that synchronous unilat-
eral tumors often are genetically similar, indicating that
they develop from a single clonal origin, but multiple
individual primary carcinomas might also develop syn-
chronously in the same breast, confirming earlier studies
[8,16,19,36].
Only one of eight synchronously diagnosed bilateral
breast tumor pairs displayed genomic similarities in the
clustering analysis. Based on clinical as well as histopatho-
logical variables, this patient most likely presented with
generalized disease, further underscoring the clonal relat-
edness between the tumors. This patient also received
radiation and chemotherapy prior to surgery, which may
potentially have affected the genomic analyses; however
this does not seem to be the case because no pathological
response to the treatment was observed. Histopathologi-
cal parameters that support the notion of contralateral
spread include positive lymph nodes on both sides, the
same histological grade (3) and type (ductal carcinoma),
all of which have been suggested as evidence for meta-
static disease [1,3]. In contrast, both tumors displayed
intraductal carcinoma, one of the criteria used to deter-BMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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mine lesions of independent origin in bilateral breast can-
cer [1].
Earlier studies of bilateral breast cancer have demon-
strated a failure to provide unambiguous evidence for the
distinction between independent tumors and contralat-
eral spread based on histopathological parameters
[10,14,15]. Of the tumor biological and histopathological
parameters investigated in our study, DNA index and his-
tological type correlated with the genetically based cluster-
ing outcome. Specifically, all six tumor pairs that
displayed genomic similarities within the pair also had
highly similar DNA indices, and both tumors within the
pair were of the same histological type in these cases.
Among the tumors that did not illustrate pair-wise
genomic similarities in the clustering analysis, two tumor
pairs had different histological types (tumors 1b and 4a
were of lobular type and tumors 1a and 4b were of ductal
type), and seven of ten tumor pairs displayed large differ-
ences in DNA index within the tumor pairs. Tumor size,
hormone receptor status, distance between tumors (for
unilateral tumors) and lymph node status were inconclu-
sive or did not correlate with the results of the genomic
analysis. Nevertheless, one study has demonstrated that
the distance between the tumors might be of significance
when discriminating between independent tumors and
intramammary dissemination in multi-focal or multi-cen-
tric unilateral tumors; the study was however very small
and no significance was reached [8].
Since tumor histology (type and grade) is inconclusive in
most cases of multiple tumors in the same breast, it is dif-
ficult to discriminate between the development of multi-
ple primary lesions and lesions developed from the same
tumor origin. Based on the notion that intraductal cancer
constitutes a pre-invasive phase in breast cancer progres-
sion, it has been suggested that the presence of intraductal
components in each of the lesions indicates independent
origins [7,8]. However, more recent studies suggest that
the occurrence of an intraductal component is of little
help in distinguishing multiple independent tumors from
intramammary dissemination [16,35,36]. The fact that
intraductal carcinoma occurred at the same frequency in
clustered pairs as in non-clustered pairs in our study (four
of five vs. three of five), together with the observation that
the grade of the intraductal component was similar to that
of the corresponding invasive component, suggests that
the intraductal component represents an intraductal
growth phase rather than pre-invasive in situ cancer and
confirms the view put forward in the latter studies. By his-
topathological examination, it is very difficult to distin-
guish between pre-invasive carcinoma in situ and
intraductal spreading of invasive components. However,
in our study, the unilateral tumor pairs that clustered
together (four of five) demonstrated vessel invasion while
none of the pairs that did not cluster displayed this fea-
ture, suggesting a common origin of the tumors that clus-
tered together. This stresses the importance of
determining the ability of a tumor to spread and invade
surrounding tissue by distinguishing between a pre-inva-
sive in situ component and intraductal spreading by eval-
uating vessel invasion in conjunction with the intraductal
component.
Even if a majority of unilateral breast tumors arise
through intramammary dissemination of a single breast
cancer a significant number of synchronous unilateral
tumors could, according to our study, have developed
from independent origins. This might be important to
consider when evaluating the clinical outcome of the
patient. Our findings demonstrate the importance of eval-
uating the properties of both tumors in order to deter-
mine the most optimal treatment for the patient. The
possibility of synchronous unilateral tumors representing
individual clones could have implications for the clinical
outcome of the patient if both tumors are not accurately
characterized. Using a PCR-based approach, it was
recently shown that clonally related ipsilateral recurrences
were more frequently of higher histological grade and
developed sooner after initial treatment than clonally dis-
tinct ipsilateral recurrences [9], and it has also been
reported that women with clonally related ipsilateral
recurrences had poorer outcomes than patients with unre-
lated tumor pairs [37]. In the present study, all the unilat-
eral tumor pairs that clustered together were histological
grade 3, while the non-clustering tumor pairs were low to
moderate histological grade (see Table 1). Molecular
approaches may hence provide a reliable means of identi-
fying patients who may benefit from more aggressive sys-
temic treatment, i.e. whose tumors are clonally related
and more likely to be associated with metastatic disease.
Of interest, a recent study of 22 pairs of ipsilateral breast
cancers revealed a statistical difference in metastasis-free
survival between new primary tumors and recurrences as
defined by a 'partial identity score' based on DNA break-
point information, suggesting that genomic analyses
could outperform clinical and histopathological charac-
teristics in terms of prediction of prognosis [38], and sup-
porting our conclusions. The importance of correctly
characterizing the individual synchronous tumors is also
apparent in bilateral breast cancer. Even if rare, bilateral
metastatic spread seems to occur, and since metastatic dis-
ease is known to result in a worse prognosis it is important
to consider the occurrence of metastatic disease in these
cases by analyzing both tumors. Our results clearly dem-
onstrate that through the evaluation of both tumors in the
pair by genome-wide aCGH and hierarchical clustering
analysis one might obtain objective information regard-
ing whether the tumors are independent lesions or dis-
seminated disease.BMC Clinical Pathology 2008, 8:6 http://www.biomedcentral.com/1472-6890/8/6
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Conclusion
In conclusion, we report that by using tiling aCGH we can
obtain an objective measure of genetic similarity in syn-
chronously diagnosed multiple breast tumors. Unilateral
tumors with highly similar genomic profiles are thought
to share a common origin, while the development of sep-
arate primary unilateral breast tumors also occurs based
on the genomic dissimilarity within the pairs in these
cases. Conversely, synchronous bilateral tumors are most
likely individual primary tumors, but contralateral dis-
semination does occur. Moreover, we found that standard
pathological evaluation does not allow a firm determina-
tion of clonal relationships among synchronously diag-
nosed breast tumors, and there was a high level of
discordance between conventional parameters and the
genetic analysis. A larger study is needed to definitely con-
firm or refute correlations between conventional his-
topathological criteria and aCGH-based genomic
analyses. We propose that unsupervised hierarchical clus-
tering of aCGH profiles can be used as an objective
method to complement standard pathological diagnoses
when attempting to reveal clonal relationships among
synchronous breast tumors.
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